Gilead Appoints Cindy Perettie Executive Vice President of Kite
May 16 2023 - 3:01PM
Business Wire
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Cindy
Perettie will join the company as Executive Vice President of Kite,
a Gilead Company, overseeing the cell therapy business, and will
become a member of Gilead’s senior leadership team, effective May
30.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230516005214/en/
Gilead Appoints Cindy Perettie Executive
Vice President of Kite (Photo: Business Wire)
Ms. Perettie brings with her extensive experience in oncology
and a commitment to improving patient care. Most recently, she was
Head of Roche’s Molecular Lab Solutions where she oversaw the PCR
(polymerase chain reaction) and Sequencing Business. Prior to that,
she was Chief Executive Officer at Foundation Medicine. Before
joining Foundation Medicine, Ms. Perettie was Head of Global
Oncology Strategy at Roche’s Oncology Unit, where she led one of
the largest global oncology portfolios in the industry. In 2012,
Ms. Perettie joined Sarah Cannon Research Institute as President of
Global Development Innovations where she gained invaluable insights
into the day-to-day care of people living with cancer. She started
her career at Johns Hopkins University as a senior research
associate.
“Cindy has more than 20 years’ experience in scientific and
commercial leadership in oncology and has dedicated her career to
improving the care of cancer,” said Daniel O’Day, Chairman and
Chief Executive Officer of Gilead. “With her extensive experience,
her passion for patients and her outstanding leadership skills,
Cindy is the right leader to build on our global leadership in cell
therapy so that more eligible patients can benefit from this
potentially curative treatment.”
“I am looking forward to working with the team as we realize the
full potential of what cell therapy can offer to patients,” said
Ms. Perettie. “As the established global leader in cell therapy,
Kite has made tremendous strides in developing and delivering two
treatments across five indications. The cell therapy business
continues to play an important role in Gilead’s ambition to become
a top oncology company. I believe with the continued focus and
commitment of the Kite team we will be able to reach many more
cancer patients around the world.”
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has
pursued and achieved breakthroughs in medicine for more than three
decades, with the goal of creating a healthier world for all
people. The company is committed to advancing innovative medicines
to prevent and treat life-threatening diseases, including HIV,
viral hepatitis and cancer. Gilead operates in more than 35
countries worldwide, with headquarters in Foster City,
California.
For more information about Gilead, please visit
the company’s website at www.gilead.com, follow Gilead on Twitter
(@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5
or 1-650-574-3000.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230516005214/en/
Jacquie Ross, Investors investor_relations@gilead.com
Ashleigh Koss, Media public_affairs@gilead.com
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Apr 2023 to Apr 2024